Table 1.
Baseline patient demographics, C. difficle characteristics, and laboratory markers at diagnosis for the overall cohort and quartiles of increasing serum 25-hydroxyvitamin D level.
| Total cohort (n=67) | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | |
|---|---|---|---|---|---|
| Patient characteristics | |||||
| Age (y, median, range) | 59 (20-88) | 52 (24-78) | 56 (25-87) | 69 (24-88) | 62 (20-81) |
| Male gender (n, %) | 32(48) | 8(47) | 9(53) | 10(63) | 5(29) |
| White race (n, %) | 58(87) | 14(82) | 16(94) | 14(88) | 14(82) |
| Serum 25-hydroxyvitamin D (ng/mL, mean, SD) | 26.1 (18.54) | 12.27 (1.16) | 18.11 (2.13) | 24.43 (1.86) | 48.96 (24.41) |
| Vitamin D supplementation (n, %) | 21(31) | 5(29) | 5(29) | 1(6) | 10(59) |
| Charlson-Deyo score1 (mean, SD) | 2 (1.45) | 1.82 (1.74) | 2.12 (1.73) | 1.75(1) | 2.29 (1.21) |
| Renal disease (n, %) | 9(13) | 3(18) | 2(12) | 3(19) | 1(6) |
| Malignancy (n, %) | 21(31) | 2(12) | 5(29) | 6(38) | 8(47) |
| ECF resident (n, %) | 13(19) | 3(18) | 4(24) | 5(31) | 1(6) |
| Weight (kg, mean, SD) | 78.8 (22.6) | 84.1 (28.3) | 86.6 (23.5) | 74.5 (16.9) | 69.5 (17.2) |
| BMI (mean, SD) | 27.3 (7.7) | 28.7 (9.6) | 30.9 (8.9) | 25.2 (4.9) | 24.6 (4.9) |
| Hospitalization within previous 4 weeks (n, %) | 21(31) | 3(18) | 6(35) | 7(44) | 5(29) |
| CDI characteristics | |||||
| CA CDI (n, %) | 9(13) | 2(12) | 2(12) | 3(19) | 2(12) |
| HO-HA CDI (n, %) | 33(49) | 10(59) | 8(47) | 9(56) | 6(35) |
| Diagnosis by detection of stool toxin by EIA (n, %) | 33(49) | 9(53) | 9(53) | 9(56) | 6(35) |
| Diagnosis by PCR for tcdB (n, %) | 34(51) | 8(47) | 8(47) | 7(44) | 11(65) |
| Ribotype 014-020 (n, %) | 10(15) | 2(12) | 2(12) | 3(19) | 3(18) |
| Ribotype 027 (n, %) | 6(9) | 2(12) | 2(12) | 1(6) | 1(6) |
| Initial management with vancomycin (n, %) | 24(36) | 6(35) | 4(24) | 9(56) | 5(29) |
| Laboratory parameters | |||||
| WBC (1000/µL, median, range) | 10.3 (0.2-66.4) | 12.2 (4.6-56.3) | 9.8 (0.8-45.1) | 10.1 (0.2-66.4) | 7.1 (1.3-18.3) |
| Hgb (g/dL, median, range) | 9.5 (6.5-15.4) | 8.8 (7.4-15.4) | 9.3 (7.2-13.1) | 8.3 (6.5-11.8) | 10.1 (7.1-14.2) |
| Platelet count (1000/µL, median, range) | 259 (19-1145) | 286 (56-664) | 284 (83-524) | 256 (19-1145) | 196 (38-593) |
| Albumin (g/dL, median, range) | 3.3 (1.9-4.6) | 2.9 (1.9-4) | 3.4 (2.8-4.6) | 3.3 (2.4-4.3) | 3.6 (2.7-4.4) |
| Creatinine (mg/dL, median, range) | 0.9 (0.4-5.2) | 1.1 (0.4-4) | 1.1 (0.7-5.2) | 1 (0.6-4.4) | 0.7 (0.5-1.6) |
BMI, body mass index in kg/m2; CA, community-associated; CDI, Clostridium difficile infection; ECF, extended care facility; EIA, enzyme immunoassay; Hgb, hemoglobin; HO-HA, healthcare facility-onset, healthcare facility-associated; PCR, polymerase chain reaction; SD, standard deviation; y, years. 1weighted comorbidity index.